Is the American cannabis sector facing the prospect of just a few players dominating the market? While worries abound in some corners of the space, sources say that is not the current case.
Alan Brochstein, founder of 420 Investor and New Cannabis Ventures, told Benzinga that while a single dominant player would be bad for cannabis, no state currently faces that prospect.
"There are, however, states that have a few players that may dominate, especially early, but this tends to get resolved over time as competitors mature," he said.
Despite no state facing a single operator running its market, concerns remain, with advocates worried that competition will fall by the wayside.
One state, Florida, is often used as an example of the pros and cons of a supposed single player dominating a market.
Several MSOs have entered the Florida medical market in recent years, with Trulieve Cannabis Corp (OTC: TCNNF) outpacing the pack by a substantial sum. As reported by Marijuana Business Daily, September 2022 data from the state Office of Medical Marijuana Use shows that Trulieve operates 120 dispensaries. MÜV (59), Curaleaf Holdings Inc (OTC: CURLF) (51) and Liberty Health and Sciences (51) rounded out the top four.
Despite the company's strong dispensary presence, respondents weren't concerned.
"That market is pretty fully vertically integrated, which can lead to dominance in the early days," said Brochstein, offering data showing that Trulieve's market share has declined as other operators increase production capabilities.
Despite any possible declines in market dominance, Trulieve has a substantial lead on medical cannabis sold in Florida. From May 2019 to September 2022, the company sold 12.1 billion milligrams of THC. In second was Curaleaf, selling 3.3 billion milligrams during the period.
While dominant, operators and investors say Trulieve leaves room for other names to prosper in the market.
Michael Sassano, CEO of Somai Pharmaceuticals, said Florida is an ideal example of how a company can capture a significant market share while allowing other companies to thrive.
"Big players are always good anchors, but their presence does not hamper growth," he said.
Morgan Paxhia, co-founder and managing director at Poseidon and AdvisorShares Poseidon Dynamic Cannabis ETF (NYSEARCA: PSDN), said companies that focused on scaling in a specific market have gained "large enterprise value, momentum and operating leverage," but not complete market control.
Undeterred by major players, Poseidon recently invested in the Florida brand Sunburn. Paxhia noted a possible adult use legalization vote in 2024 and sales starting in 2025 as prime factors.
"We see it as a market with room remaining for strong operators offering unique products," he said.
Various sources discussed other states. Illinois was the second-most mentioned.
A few names compete for market dominance in Illinois, but one company is outpacing the pack, like Florida. With the most enormous production canopy in the state and a growing national brand, Cresco Labs Inc (OTC: CRLBF) is seen as a dominant market force.
Today, the company has the potential to reach up to 630,000 square feet of cultivation canopy in Illinois.
However, like Florida, sources don't see Cresco's dominance as a sign of a single company taking over the market. Brochstein notes that dispensary caps limit Cresco or any other player from controlling the entire Illinois market. The company currently operates ten stores across the state.
"That market isn't suffering at all from domination at this time," Brochstein said.
Neither Trulieve nor Cresco provided comments for this article.
The amount of operators does not correlate to market success. Instead, Chris Becker, co-founder and sales director for Colorado cannabis brand The Honeybee Collective said numerous factors determine how a market's health and success are quantified.
Becker said that various factors might measure market performance depending on who is analyzing the results. He cited several possible metrics, including tax revenue generation, company balance sheets and the levels of unlicensed market activity post-legalization.
"Some of these metrics might be in conflict with one another, like protecting company profits vs. disappearing the illicit market," he said.
Operators and investors offered various takes on ideal markets. Becker supports open marketplaces with few or no dominant names.
"I tend to believe consumers are better off when there's a competitive market that's not monopolized by a few players," he said.
Brochstein also highlighted Colorado, citing strong supplies and profitable companies.
On the other hand, he said Oklahoma's high number of suppliers leaves little room for profit. Brochstein also noted, "Consumers benefit from the high number of supplies."
Somai Pharmaceuticals' Sassano prefers a semi-capped market.
"Open markets like Oregon and Washington have suffered with closures, while limited license markets like New York and New Jersey failed early on," Sassano said. He highlighted Nevada's fixed license with trade capabilities rules as ideal.
John Yang, CEO of the e-commerce platform Treez called for a market balance.
"Larger operators bring scale, normalization and attention to the space, while smaller players typically bring the culture and choice that consumers are looking for and bridge the gap between legacy and legal markets," he said.
Still, Yang cautioned that balance isn't a sign of market success.
"California is certainly an example of having both but is struggling due to other factors – economic forces, taxation, the illicit market, et cetera," he said, citing optimism for New York's soon-to-launch adult-use market.
Photo by Terrance Barksdale: https://www.pexels.com/photo/marijuana-in-glass-jar-9146962/
Are Cannabis Companies Paying Their Contractors?
With More Cannabis Industry Layoffs Likely, What Can You Do To Stay Employed?
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The health department is still trying fill 25 open positions and currently only has three staffers and zero investigators looking at the medical pot program in the state. Here’s more.
Cannabis stocks and ETFs gained momentum to start the fourth quarter thanks to President Joe's announcement of a historic marijuana reform.
Walgreens Boots Alliance is doubling down on its big healthcare bet as the pharmacy giant upped a long-term sales target for its growing healthcare business.
In this article, we discuss the 10 large-cap stocks to buy according to billionaire Richard Chilton. If you want to skip our detailed analysis of Chilton’s history, investment philosophy, and hedge fund performance, go directly to the 5 Large-Cap Stocks to Buy According to Billionaire Richard Chilton. Richard Chilton was born in New Jersey, America, […]
Inflation and higher interest rates could be here to stay. BofA says changing demographics, deglobalization, and underinvestment in energy production have created a new “regime” for the global economy.
The U.S. stock market took an unusual swing after Thursday’s inflation report. “Shortly after the open, the S&P 500 index had dropped nearly 4% from its pre-market highs before staging an epic rally of over 5%,” Bespoke Investment Group said in a note Friday. “Even in this ‘all or nothing’ type of market environment, reversals of that magnitude are rare.”
MarketWatch Picks has highlighted these products and services because we think readers will find them useful; the MarketWatch News staff is not involved in creating this content. And at a 2009 shareholder meeting, Buffett noted that the first best thing you can do to protect against inflation is to invest in yourself and your skills: “If you’re the best teacher, if you’re the best surgeon, if you’re the best lawyer, you will get your share of the national economic pie regardless of the value of whatever the currency may be,” he said.
Investors seemingly can’t stop trying to pick a stock market bottom, no matter how bad the news—and it continues to backfire. Consider: This past Thursday, September’s consumer inflation report came in much hotter than expected, with the core CPI hitting a 40-year high. The initial response was exactly what you’d expect—the traded down as much as 2.4%—but then it started rallying…and rallying.
Investors were surprised by the big rally in the stock market on Thursday, but Friday brought another dose of reality and disappointment. After having posted monumental gains despite high readings on inflation, the Nasdaq Composite (NASDAQINDEX: ^IXIC) closed at its worst level of the year, and the S&P 500 (SNPINDEX: ^GSPC) and Dow Jones Industrial Average (DJINDICES: ^DJI) gave up most of their advances from earlier in the week. One of the biggest stock stories of the past several years has been Tesla (NASDAQ: TSLA).
Being patient doesn't always pay off.
Everyone is hoping the market might be bottoming and by the recent actions of Bank of America clients, some evidently think the lows must be in sight. Last week, BofA customers splashed out $6.1 billion on US stocks, in what amounted to the third largest inflow since 2008. While the bank has stated it is not as confident the bottom is quite so close, it’s not hard to see why investors feel the time is right to lean into equities. The widespread losses have left scores of beaten-down stocks looki
Shares of electric vehicle (EV) manufacturer Rivian (NASDAQ: RIVN) sank in Friday morning trading. At that time, the tech-heavy Nasdaq Composite was down by 2.3%. A number of factors were working against Rivian's shares.
Nikola (NKLA) founder Trevor Milton was found guilty of three counts of criminal fraud on Friday in a case accusing him of spreading lies about the electric truck startup for his own personal benefit.
These diversified natural-resource giants have solid balance sheets, earnings, and dividends. All that they need is a rebound in commodity prices.
The stock market is reeling from the pressures of a potential global recession, and central banks around the world are gearing up for the most aggressive interest rate hikes in history. The United Nations recently warned that the world is “on the edge of a recession,” which will likely be worse than the pandemic-driven recession in 2020 or the global financial crisis of 2008. Understandably, U.S. equities have taken a hit, with the S&P 500 index registering the worst monthly performance in Septe
Making investments pay out for the long term is the true challenge in today’s market environment. The series of headwinds piling up – from persistently high inflation to rising interest rates to slowing demand to bureaucratic bloat – are rising to hurricane force, and renewing investors’ attention to defensive stocks. It’s only logical. The classic defensive stock, the dividend payer, ensures an income stream no matter how the markets move, and if the yield is high enough, these stocks can also
Last month, the Federal Reserve implemented its fifth straight interest rate hike this year, and its third consecutive hike at 75 basis points, bringing its key funds rate up to the 3% to 3.25% range. The move showed that the central bank is deadly serious about taking on the stubbornly high inflation that has been plaguing the economy since the middle of 2021. The Fed’s turn toward an aggressive anti-inflationary policy may not be hard enough, however, as the September data, released this morni
Dividends are the bread and butter of income investors. You don't need to sell your assets or spend hours every day managing your accounts. Instead, dividend stocks simply generate income on their own. Putting together a portfolio that generates at least … Continue reading → The post How to Make $1,000 a Month in Dividends appeared first on SmartAsset Blog.
This week’s worse-than-expected inflation report led to turmoil in more than one market, but you only read about one of them. What got far less attention was the flurry of excitement that the inflation report caused in the normally-staid I-bond market.
Yahoo Finance Live anchors discuss the dip in stock for Tesla amid CEO Elon Musk’s ongoing Twitter trial